Lincoln Pharmaceuticals Ltd - 531633 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- NIREN DESAIDesignation :- Company Secretary and Compliance Officer Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivani B Shah LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the above captioned subject matter, pursuant to the provisions of section 124 (6) of the Companies Act, 2013 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copies of notice published in the newspaper on June 21, 2021 as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and amendments thereof, inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends for last seven consecutive years, failing which their shares would be transferred to IEPF Authority. Lincoln Pharmaceuticals Ltd - 531633 - Regulation 23 (9) - Disclosure Of Related Party Transaction For The Half Year Ended On March 31, 2021
Pursuant to Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions on a consolidated basis, in the format specified in the relevant Indian accounting standards for the half year ended March 31, 2021. Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2021. The said advertisement was published in the following newspapers: 1. The Economic Times, Ahmedabad Edition - In English; 2. Jay Hind, Ahmedabad Edition - In Gujarati. Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and SEBI Circular No. CIR/CFD/CMDi/27/2019 dated February 08, 2019, please find enclosed herewith the Annual Secretarial Compliance Report issued by M/s. Vishwas Sharma & Associates, Practicing Company Secretary (C. P. No. 16942), for the financial year ended on March 31, 2021. Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Dividend Updates
we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have Recommended a dividend of Rs. 1.50/- (i.e. 15% per share) per equity share of face value of Rs. 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company.
